Tracked deals
24
24 tracked deals across 2019-2026.
Who's Buying Biotechnology Companies in Canada
Buyer mix
Strategic-led
24 strategic · 2 pe
Top trend
Volume peaked in 2023
6 tracked deals announced in 2023.
Primary Insight
What Stands Out
Key themes across Canadian biotech deals
- Oncology and targeted therapeutics show up repeatedly, including radioconjugates (e.g., AstraZeneca / Fusion Pharmaceuticals) and small-molecule immuno-oncology programs (e.g., Eilean Therapeutics / Ness Therapeutics).
- Platform and enabling technology is a recurring driver: Recursion adds digital chemistry and generative chemistry capabilities via Cyclica and Valence, while BioLife Solutions expands biopreservation consumables through PanTHERA CryoSolutions.
- CRO and lab capability expansion appears in multiple transactions, such as BBI Solutions OEM Limited / IBEX Technologies Inc. and Mapmygenome / Microbiome Insights.
- Regional clustering across provinces is visible, with notable activity in Quebec, Ontario, British Columbia, and Alberta.
- Several deals emphasize integration of specialized operations, including GMP-ready manufacturing/R&D facilities and lab accreditation, as described in the transactions highlighted for Ontario and British Columbia.
Build a buyer list for your Biotechnology deal
Find buyers actively acquiring biotechnology companies.
Find buyers like these for your dealBuyer Snapshot
Top Buyers
Illustrative buyers pulled from tracked transactions on this page. This table is capped and intentionally non-exhaustive.
| Buyer | # Deals | Focus | Type |
|---|---|---|---|
| Acuitas Therapeutics | 1 | Developer and provider of lipid nanoparticle (LNP) delive... | Strategic |
| AstraZeneca | 1 | Global biopharmaceutical company focused on discovery, de... | Strategic |
| BBI Solutions OEM Limited | 1 | Global manufacturer of immunodiagnostic reagents and cust... | Strategic |
| BioLife Solutions, Inc. | 1 | Public company supplying cell processing tools, biopreser... | Strategic |
| Core One Labs Inc. | 1 | Public biotechnology company focused on psychedelic medic... | Strategic |
| Danaher Corporation | 1 | Global science and technology company focused on life sci... | Strategic |
| Delic Holdings Inc. | 1 | Publicly traded psychedelic wellness platform operating m... | Strategic |
| Eilean Therapeutics LLC | 1 | Biopharmaceutical company focused on discovering and deve... | Strategic (PE-backed) |
| Elanco Animal Health Incorporated | 1 | Global animal health company providing products and knowl... | Strategic |
| Enveric Biosciences | 1 | Public biotechnology company developing novel cannabinoid... | Strategic |
Acquisition Volume in Biotechnology in Canada by Year
Last 8 years
Actual
Full-year estimate
Supporting Data
Recent Transactions
-
- Buyer
- Acuitas Therapeutics
- Target
- RNA Technologies & Therapeutics (RNA T&T)
- Industry
- Biotechnology
- Location
- Quebec, Canada
- Type
- Buyout
Acuitas Therapeutics has acquired a majority stake in RNA Technologies & Therapeutics (RNA T&T), deepening a long-standing collaboration to integrate RNA payload design and LNP delivery capabilities. The investment will support RNA T&T's growth—expanding its algorithmic RNA-sequence optimization platform and small-batch GMP production—while both companies continue to operate independently and offer streamlined capabilities to partners.
-
November 3, 2025
- Buyer
- Pacific Software, Inc. (dba PurMinds Enterprises, Inc.)
- Target
- PurMinds Holdings Inc., 10763942 Canada, Inc.
- Industry
- Biotechnology
- Location
- Ontario, Canada
- Type
- Buyout
Pacific Software, Inc. completed a change of control and reverse takeover (RTO) transaction with PurMinds Holdings Inc., finalizing the acquisition effective November 3, 2025 and rebranding the public company as PurMinds Enterprises, Inc. The combined company has taken occupancy of a 20,477 sq. ft. cGMP-ready pharmaceutical manufacturing and R&D facility and is pursuing OTCQX uplisting and PCAOB-audited financials to support its clinical-stage neuromedicine strategy.
-
May 29, 2025
- Buyer
- Mapmygenome
- Target
- Microbiome Insights
- Industry
- Biotechnology
- Location
- British Columbia, Canada
- Type
- Buyout
Mapmygenome, an AI-driven genomics company based in Hyderabad, India, has acquired Microbiome Insights, a Canadian microbiome sequencing and bioinformatics CRO with a CAP-accredited lab. The deal expands Mapmygenome's capabilities in metagenomics and bioinformatics and accelerates its geographic expansion into North America; financial terms were not disclosed.
-
April 10, 2025
- Buyer
- BioLife Solutions, Inc.
- Target
- PanTHERA CryoSolutions, Inc.
- Seller
- PanTHERA CryoSolutions shareholders
- Industry
- Biotechnology
- Location
- Alberta, Canada
- Type
- Buyout
BioLife Solutions acquired the remaining 90% of PanTHERA CryoSolutions for $9.3 million in cash plus 241,355 shares of BioLife common stock, with up to an additional $7.2 million of stock payable upon achievement of milestones. The acquisition adds PanTHERA's proprietary Ice Recrystallization Inhibitor (IRI) technology and scientific talent to BioLife's biopreservation consumables portfolio, accelerating product capability development for the cell and gene therapy market.
-
April 8, 2024
- Buyer
- BBI Solutions OEM Limited
- Target
- IBEX Technologies Inc.
- Industry
- Biotechnology
- Location
- Quebec, Canada
- Type
- Buyout
BBI Solutions OEM Limited has acquired IBEX Technologies Inc., a Montreal-based developer and manufacturer of high-precision enzymes and diagnostic solutions, with the transaction closing on April 8, 2024. The acquisition expands BBI's recombinant protein and enzyme capabilities to better serve in-vitro diagnostics (IVD) manufacturers and brings IBEX's staff and contract-manufacturing capabilities into BBI's global operations.
-
March 19, 2024
- Buyer
- AstraZeneca
- Target
- Fusion Pharmaceuticals Inc.
- Industry
- Biotechnology
- Location
- Ontario, Canada
- Type
- Buyout
AstraZeneca has entered into a definitive agreement to acquire Fusion Pharmaceuticals Inc., a clinical-stage company developing next-generation actinium-based radioconjugates, for $21.00 per share in cash plus a non-transferable contingent value right that could bring the total to approximately $2.4 billion. The acquisition adds Fusion's pipeline (including FPI-2265 for mCRPC), R&D and manufacturing capabilities in radioconjugates and strengthens AstraZeneca's oncology portfolio and presence in Canada.
-
March 4, 2024
- Buyer
- Eilean Therapeutics LLC
- Target
- Ness Therapeutics Inc
- Industry
- Biotechnology
- Location
- Ontario, Canada
- Type
- Buyout
Eilean Therapeutics LLC acquired Ness Therapeutics Inc in an all-equity transaction to obtain Ness’s preclinical PTPN2 inhibitor program. The acquisition expands Eilean’s immuno-oncology pipeline and capabilities in small-molecule inhibitors targeting resistance mechanisms in hematologic and solid malignancies.
-
August 31, 2023
- Buyer
- Otsuka Pharmaceutical Co., Ltd., Otsuka America, Inc.
- Target
- Mindset Pharma Inc.
- Industry
- Biotechnology
- Location
- Ontario, Canada
- Type
- Buyout
Otsuka Pharmaceutical Co., Ltd., through its wholly owned U.S. subsidiary Otsuka America, Inc., agreed to acquire Mindset Pharma Inc. in an all-cash statutory plan of arrangement valued at approximately CAD 80 million. The acquisition adds Mindset’s next-generation psychedelic and non-psychedelic drug discovery assets and synthesis capabilities to Otsuka’s psychiatry and neurology pipeline.
-
August 1, 2023
- Buyer
- Sygnature Discovery
- Target
- NuChem Sciences
- Industry
- Biotechnology
- Location
- Quebec, Canada
- Type
- Buyout
UK-based integrated drug discovery CRO Sygnature Discovery has acquired Montreal-headquartered NuChem Sciences, one of North America's largest discovery contract research organisations. The deal expands Sygnature's global footprint and capabilities in medicinal chemistry, DMPK, structural biology and in vitro/in vivo pharmacology, strengthening its position in the North American market.
-
July 25, 2023
- Buyer
- Solar Biotech Inc.
- Target
- Noblegen
- Industry
- Biotechnology
- Location
- Ontario, Canada
- Type
- Buyout
Solar Biotech Inc., a Norton, Virginia-based synthetic biology and bioprocessing company, has acquired Noblegen, an advanced digital biology and precision fermentation company based in Peterborough, Ontario. Noblegen will operate as Solar Biotech Canada and serve as the group's food-grade-certified biomanufacturing and R&D hub, expanding Solar Biotech's upstream/downstream capabilities and on‑the‑ground capacity in Canada.
-
June 1, 2023
- Buyer
- MPM BioImpact
- Target
- Reunion Neuroscience Inc.
- Seller
- Reunion shareholders
- Industry
- Biotechnology
- Location
- Ontario, Canada
- Type
- Buyout
Affiliates of biotechnology investor MPM BioImpact agreed to acquire clinical-stage biopharmaceutical company Reunion Neuroscience in an all-cash take-private transaction valued at about US$13.1 million. Reunion shareholders will receive US$1.12 per share in cash; MPM said the acquisition will support advancement of Reunion's lead psychedelic therapeutic RE104 into Phase 2 clinical development.
-
- Buyer
- Recursion
- Target
- Cyclica, Valence
- Industry
- Biotechnology
- Location
- Canada
- Type
- Buyout
Recursion (NASDAQ: RXRX) entered into agreements to acquire two AI-enabled drug discovery companies, Cyclica (Toronto) and Valence (Montréal), for aggregate reported purchase prices of $40.0 million and $47.5 million respectively, payable primarily in Recursion equity and exchangeable subsidiary shares. The acquisitions add digital-chemistry, proteome-wide prediction and low-data generative chemistry capabilities to Recursion's RecursionOS and research organization to accelerate its AI-first drug discovery platform.
-
April 18, 2023
- Buyer
- GSK plc
- Target
- BELLUS Health Inc.
- Industry
- Biotechnology
- Location
- Quebec, Canada
- Type
- Buyout
GSK plc entered into an agreement to acquire BELLUS Health Inc. in a cash deal valued at approximately US$2.0 billion (US$14.75 per share). The acquisition is intended to give GSK access to camlipixant, a late-stage (phase III) highly selective P2X3 antagonist for refractory chronic cough, with anticipated regulatory approval and launch in 2026 and expected EPS accretion from 2027.
-
October 31, 2022
- Buyer
- NuChem Sciences, Fonds de solidarité FTQ
- Target
- IniXium
- Industry
- Biotechnology
- Location
- Québec, Canada
- Type
- Buyout
Montreal-based contract research organization NuChem Sciences has acquired IniXium of Laval, Québec, with investment support from the Fonds de solidarité FTQ. The deal expands NuChem's structural biology and recombinant protein production capabilities—integrating IniXium's crystallography and fragment screening expertise into NuChem's drug-discovery services.
-
February 23, 2022
- Buyer
- Isracann Biosciences Inc.
- Target
- Praesidio Health Inc.
- Industry
- Biotechnology
- Location
- Canada
- Type
- Buyout
Isracann Biosciences Inc. entered into a binding letter of intent to acquire Canadian medical research company Praesidio Health Inc. under a stock transaction valued at approximately CAD 4.0 million. Praesidio develops and validates evidence-based natural health medicines (including formulations with cannabinoids and/or psilocybin) for conditions such as urological disorders, anxiety/stress, immune support and sleep.
-
February 11, 2022
- Buyer
- Core One Labs Inc.
- Target
- Awakened Biosciences Inc.
- Seller
- Shareholders of Awakened Biosciences Inc.
- Industry
- Biotechnology
- Location
- Ontario, Canada
- Type
- Buyout
Core One Labs Inc. (CSE: COOL) has completed the acquisition of all outstanding share capital of Awakened Biosciences Inc., adding Awakened's provisional patents and novel synthetic psilocybin production technologies to Core One's portfolio. The deal expands Core One's R&D and manufacturing capabilities in psychedelic therapeutics and secures IP that could enable lower-cost, scalable production and potential near-term revenue from non-controlled psilocybin-based compounds.
-
December 22, 2021
- Buyer
- Organigram Holdings Inc.
- Target
- Hyasynth Biologicals Inc.
- Industry
- Biotechnology
- Location
- Quebec, Canada
- Type
- Growth capital
Organigram Holdings Inc. has invested an additional $2.5 million in secured convertible debentures of Hyasynth Biologicals Inc., bringing its total investment to $10.0 million. The financing is intended to advance Hyasynth's production scalability, R&D into rare cannabinoids and commercial partnerships as the company scales fermentation-based cannabinoid manufacturing.
-
June 1, 2021
- Buyer
- Danaher Corporation
- Target
- Precision NanoSystems
- Industry
- Biotechnology
- Location
- British Columbia, Canada
- Type
- Buyout
Danaher Corporation has acquired Vancouver-based Precision NanoSystems (PNI), a developer of lipid nanoparticle delivery technologies and microfluidic manufacturing platforms for genetic medicines. PNI will join Danaher's Life Sciences platform to expand its capabilities in mRNA and genetic-medicine development and complement existing portfolio companies such as Cytiva and Pall.
-
- Buyer
- Delic Holdings Inc. (DELIC)
- Target
- Complex Biotech Discovery Ventures Ltd. (CBDV) / DELIC Labs
- Seller
- Shareholders of Complex Biotech Discovery Ventures Ltd.
- Industry
- Biotechnology
- Location
- British Columbia, Canada
- Type
- Buyout
Delic Holdings Inc. (DELIC), a publicly traded psychedelic wellness platform based in Vancouver, has acquired all issued and outstanding shares of Complex Biotech Discovery Ventures Ltd. (CBDV), a Vancouver-based licensed psilocybin and cannabis research laboratory, for a closing payment of $7.0 million plus up to $3.0 million of earn-out consideration. CBDV will be rebranded as DELIC Labs and will serve as Delic's R&D and IP engine for psilocybin and cannabis extraction, analytical testing, and chemical process development.
-
May 24, 2021
- Buyer
- Enveric Biosciences
- Target
- MagicMed Industries Inc.
- Seller
- MagicMed shareholders
- Industry
- Biotechnology
- Location
- Alberta, Canada
- Type
- Buyout
Enveric Biosciences entered into a definitive all-stock agreement to acquire MagicMed Industries, a Calgary-based biotechnology company focused on psychedelic-derived drug discovery, in an amalgamation that will make MagicMed an indirect wholly owned subsidiary of Enveric. The deal expands Enveric’s pipeline beyond cannabinoids into psychedelic-derived molecules (psilocybin, DMT derivatives, etc.), includes issuance of Enveric common stock and equity awards to MagicMed shareholders, and contemplates leadership changes with Dr. Joseph Tucker named CEO upon closing.
-
- Buyer
- X-Chem, Inc.
- Target
- IntelliSyn, AviSyn
- Seller
- Shareholders of IntelliSyn and AviSyn
- Industry
- Biotechnology
- Location
- Quebec, Canada
- Type
- Addon
X-Chem, a portfolio company of GHO Capital, has acquired Montreal-based IntelliSyn and its US-based sister company AviSyn to extend its drug discovery offering into medicinal chemistry, custom synthesis and scale-up process chemistry. The deal integrates downstream hit validation and lead optimisation capabilities into X-Chem’s DNA-Encoded Library (DEL) platform, enabling a streamlined screen-to-lead service for pharma and biotech clients; financial terms were not disclosed.
-
- Buyer
- Igenomix
- Target
- Access Genomics (Access Genomics Canada)
- Seller
- Persistence Capital Partners
- Industry
- Biotechnology
- Location
- Ontario, Canada
- Type
- Buyout
Igenomix, a Spanish reproductive-genetics company, acquired Toronto-based laboratory Access Genomics (Access Genomics Canada) from Persistence Capital Partners on December 14, 2020. The acquisition expands Igenomix’s presence in North America and strengthens its ability to serve fertility clinics in the Toronto area.
-
August 1, 2019
- Buyer
- Elanco Animal Health Incorporated
- Target
- Prevtec Microbia Inc.
- Seller
- Prevtec Microbia shareholders
- Industry
- Biotechnology
- Location
- Quebec, Canada
- Type
- Buyout
Elanco Animal Health acquired Montreal-based Prevtec Microbia, maker of the Coliprotec swine E. coli vaccine line, in an all-cash transaction of CAD $78.5 million (approx. $59.9M USD) plus contingent payments of up to CAD $21.5 million. The deal brings Prevtec's commercial vaccines and R&D pipeline into Elanco to expand its swine portfolio and provide non-antibiotic alternatives for swine producers globally.
-
June 6, 2019
- Buyer
- NEOMED-LABS, Pacific Biomarkers (merged as NEOMED-LABS / Pacific Biomarkers)
- Target
- PAIRimmune
- Industry
- Biotechnology
- Location
- Quebec, Canada
- Type
- Addon
NEOMED-LABS / Pacific Biomarkers (NLPBI), an immunology-focused CRO, has acquired PAIRimmune, a preclinical immunology service provider based in Laval, Quebec. The acquisition strengthens NLPBI's assay development, ligand-binding and neutralization assay R&D capabilities, expands flow cytometry capacity, and enhances its preclinical and vaccine testing services.
Full Export
Purchase this data
Get the full acquisitions list for this page as CSV + XLSX.
Build a buyer list for your Biotechnology deal
Find buyers actively acquiring biotechnology companies.
Frequently Asked Questions
Which Canadian provinces are most represented in these biotech acquisitions?
Recent transactions highlight activity across Ontario, Quebec, British Columbia, and Alberta, with some deals described at the Canada level.
What kinds of acquisition targets are common in Canadian biotechnology deals?
Targets often include clinical-stage therapeutics (e.g., oncology and neurology assets), as well as enabling platforms such as digital chemistry, genomics/bioinformatics CRO capabilities, biopreservation technology, and specialized manufacturing or R&D operations.
Do the deals focus only on therapeutics, or also on R&D and manufacturing capabilities?
They include both. Examples include capability build-outs for radioconjugates (AstraZeneca), biopreservation consumables and IRI technology (BioLife Solutions), and lab/CRO expansion (Mapmygenome; BBI Solutions OEM Limited).
Are there any deals involving AI-enabled drug discovery or digital biology?
Yes. The page features Recursion acquiring Cyclica and Valence for AI-enabled digital chemistry and generative chemistry capabilities, and Mapmygenome acquiring Microbiome Insights to expand metagenomics and bioinformatics.